Melanotan I, Melanotan II, and Bremelanotide: A Melanocortin Record Map
Melanotan I, Melanotan II, and PT-141 are related to alpha-melanocyte-stimulating hormone, but they are distinct research materials. Their structures and receptor interactions must be compared separately. A melanocortin-family label does not establish receptor selectivity, equal potency, or interchangeable biological effects.
Start with the molecular changes
Alpha-melanocyte-stimulating hormone, usually written alpha-MSH, provides the reference sequence for this group of analogues. An analogue is a molecule modified relative to a reference structure. Those modifications can change how a peptide binds, how it activates a receptor, and how it behaves in an experimental system.
Melanotan I is associated in the literature with NDP-alpha-MSH, also called afamelanotide. The NDP designation points to norleucine and D-phenylalanine substitutions. Sawyer and colleagues investigated this analogue using several biological assays, including frog skin and mouse melanoma systems, and reported altered activity and resistance to serum-enzyme degradation. These were specific experimental findings, not a universal performance ranking. Original analogue study.
The naming is worth getting right. Searching only for “MT-1” may miss papers indexed under NDP-alpha-MSH, while pooling every melanocortin analogue can bring in different molecules. The peptide naming guide describes how to separate a genuine synonym from a related compound.
A ring changes the comparison
Melanotan II is a cyclic heptapeptide analogue. Dorr and colleagues identified the lactam-bridged structure in their original report. Its cyclic architecture distinguishes it from the linear NDP-alpha-MSH analogue; the numerals I and II do not indicate two strengths of one material. Original Melanotan II report.
Cyclization constrains the conformations available to a peptide. That is a chemical reason to investigate different receptor interactions, but it is not sufficient evidence to predict which biological outcome will dominate. A structural comparison needs functional measurements alongside it.
PT-141, also known as bremelanotide, is another distinct melanocortin analogue. Early work described activity at melanocortin receptors including MC3R and MC4R and investigated neuronal responses. Those observations should remain attached to the specified molecule and model. Original PT-141 research.
What “melanocortin receptor activity” leaves unspecified
A receptor-family label is only the start of an explanation. The reader still needs the receptor subtype, its species origin, the cell background, and the measured response. A binding assay asks whether a ligand interacts with the assay's receptor preparation. A signaling assay asks what happened after exposure. A downstream tissue response adds further layers between receptor engagement and the reported result.
Modern structural research makes this distinction tangible. Heyder and colleagues resolved active MC4R complexes with NDP-alpha-MSH and another peptide ligand, then combined the structures with signaling measurements from receptor mutants. The work connected particular molecular contacts to activation and coupling behavior. It did not establish that every melanocortin agonist behaves identically. MC4R structural and functional study.
Likewise, a separate structural investigation examined MC4R complexes containing alpha-MSH, afamelanotide, bremelanotide, and a small-molecule ligand. Examining multiple ligands within a defined receptor system is more informative for this question than comparing unrelated headline outcomes. Original ligand-recognition study.
Comparison table: identity, experiment, inference
| Material | Structural distinction | Useful evidence to inspect | What not to assume |
|---|---|---|---|
| Melanotan I / NDP-alpha-MSH | Linear alpha-MSH analogue with specified substitutions | Sequence identity and receptor-specific activity measurements | That activity is restricted to one receptor in every setting |
| Melanotan II | Cyclic, lactam-bridged heptapeptide analogue | Exact ring structure and functional receptor assay | That “II” means a stronger version of “I” |
| PT-141 / bremelanotide | Distinct analogue examined in melanocortin research | Compound identity, receptor context, and measured endpoint | That another analogue's result transfers unchanged |
| A catalog category | A navigation group, not a molecular structure | Individual product specifications | That neighboring products share selectivity or efficacy |
The Research Compounds collection provides a route to the individual materials. Their presence in one collection should not erase the distinctions in this table. Product pages help identify the material being discussed; the original experiment determines what scientific claim is supported.
Why potency values need their surrounding methods
It is tempting to copy a potency number into a comparison chart and rank compounds. Before doing that, check whether the values came from the same receptor and assay. Binding affinity, a half-maximal functional response, and the maximum response answer different questions. A lower concentration for one readout does not necessarily imply a larger maximum effect or broader relevance.
An especially useful reading question is: “What would have to stay constant for this comparison to be fair?” If receptor expression, measurement time, and reference ligand all differ, the numerical ranking may be less informative than it appears. A literature comparison matrix can preserve those differences instead of hiding them behind one column labeled potency.
Research limitations and material quality
The historical studies, structural experiments, and cellular assays cited here are not interchangeable evidence types. A receptor structure provides molecular detail; it does not by itself establish an organism-level outcome. A reported response in one model cannot establish a supplier product's purity, stability, or suitability for a different experiment.
For sample characterization, consult the relevant COA and the explanation of peptide COA interpretation. An analytical report should be read for what its methods actually measured. This article from NEXTWAVE PEPTIDES concerns research interpretation and does not provide human-use guidance.
FAQ
Are Melanotan I and Melanotan II the same peptide?
No. They differ in molecular architecture and identity. The names should be treated as separate compounds, not alternative strengths of the same material.
Can an MC4R paper explain every melanocortin receptor?
No. It directly informs the receptor and conditions investigated. Extension to another subtype requires corresponding evidence.
Does binding prove a functional response?
Binding and signaling are different measurements. A functional claim needs a relevant functional assay, with the receptor context stated.
Is a published drug formulation equivalent to a research catalog material?
No equivalence follows from a shared compound name. Formulation, preparation, characterization, and study context must be evaluated separately.